CNTB

Connect Biopharma Holdings Limited Ordinary Shares

1.56 USD
-0.07
4.29%
At close Updated Sep 12, 4:00 PM EDT
Pre-market
After hours
1.57
+0.01
0.64%
1 day
-4.29%
5 days
-10.86%
1 month
-31.28%
3 months
83.53%
6 months
98.73%
Year to date
28.93%
1 year
30%
5 years
-91.56%
10 years
-91.56%
 

About: Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Employees: 62

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

54% more capital invested

Capital invested by funds: $1.56M [Q1] → $2.4M (+$844K) [Q2]

31% more funds holding

Funds holding: 13 [Q1] → 17 (+4) [Q2]

0.72% less ownership

Funds ownership: 5.12% [Q1] → 4.4% (-0.72%) [Q2]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$7
349% upside
Avg. target
$7
349% upside
High target
$7
349% upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Brandon Folkes
$7
Buy
Reiterated
13 Aug 2025

Financial journalist opinion

Based on 4 articles about CNTB published over the past 30 days

Neutral
GlobeNewsWire
9 days ago
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced two poster presentations at the European Respiratory Society (ERS) Congress 2025, taking place September 27 – October 1, 2025, in Amsterdam, Netherlands and virtually.
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
Neutral
GlobeNewsWire
10 days ago
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has completed the termination of the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas, and the holders and beneficial owners of American Depositary Shares evidenced by American Depositary Receipts (“ADRs”) issued thereunder (the “Deposit Agreement”), and that the Company's ordinary shares are now directly listed on the Nasdaq Global Market (“Nasdaq”).
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
Neutral
GlobeNewsWire
17 days ago
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in the following upcoming conferences: Cantor Global Healthcare Conference 2025 Format: Fireside ChatDate: Wednesday, September 3rd, 2025Time: 3:20 p.m. ETWebcast Link: Register Here H.C.
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company) and the Jovante Woods Foundation (the Foundation) today kicked off a collaboration to expand the Foundation's asthma education program across the U.S. On this day in 2010, former Cincinnati Bengals running back Elbert “Ickey” Woods lost his 16-year-old son, Jovante, to an acute asthma attack he suffered on his way home from high school football practice. Ickey and Chandra Woods established the Foundation to raise awareness of the need for new treatments and to educate families dealing with asthma about overall treatment management.
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the potential of rademikibart to deliver differentiated efficacy and safety in patients with eosinophilic-driven type 2 asthma and COPD – – New drug application for rademikibart for the treatment of AD submitted to China's NMPA by Simcere, the Company's exclusive licensee in Greater China – – Announced plans to terminate ADR program and directly list ordinary shares on Nasdaq to better facilitate institutional visibility, eliminate ADR depositary fees, and strengthen ability to expand investor base – – Appointed industry veteran Jim Schoeneck to Board of Directors, bringing deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and six months ended June 30, 2025, and provided a business update. “In the second quarter, we made significant progress across our clinical and corporate goals,” said Barry Quart, Pharm.D.
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Positive
Zacks Investment Research
1 month ago
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
Does Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth – SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the expansion of the size of its Board of Directors from six to seven directors and the appointment of Jim Schoeneck as a director effective today. “We are pleased to welcome Jim to our Board of Directors,” said Kleanthis G.
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it plans to terminate the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas (the “Depositary”), and the holders and beneficial owners of American Depositary Shares (“ADSs”) evidenced by American Depositary Receipts (“ADRs”) issued thereunder (the “Deposit Agreement”).
Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29th, 2025 at 9:20 a.m. ET.
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). On July 16, 2025, the Company received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, as of July 15, 2025, the Company's American Depositary Shares (“ADSs”) maintained a minimum closing bid price of at least $1.00 for a minimum of 10 consecutive business days.
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Charts implemented using Lightweight Charts™